Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Revenue (2016 - 2025)

Mimedx (MDXG) has disclosed Revenue for 15 consecutive years, with $118.1 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 27.11% to $118.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $418.6 million through Dec 2025, up 19.99% year-over-year, with the annual reading at $418.6 million for FY2025, 19.99% up from the prior year.
  • Revenue hit $118.1 million in Q4 2025 for Mimedx, up from $113.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $118.1 million in Q4 2025 to a low of $50.8 million in Q4 2021.
  • Historically, Revenue has averaged $79.9 million across 5 years, with a median of $81.5 million in 2023.
  • Biggest five-year swings in Revenue: dropped 25.87% in 2021 and later surged 46.37% in 2022.
  • Year by year, Revenue stood at $50.8 million in 2021, then surged by 46.37% to $74.4 million in 2022, then increased by 16.75% to $86.8 million in 2023, then rose by 7.0% to $92.9 million in 2024, then grew by 27.11% to $118.1 million in 2025.
  • Business Quant data shows Revenue for MDXG at $118.1 million in Q4 2025, $113.7 million in Q3 2025, and $98.6 million in Q2 2025.